Condition: Primary Breast Cancer · Recurrent/Metastatic Breast Cancer · Sponsor: Cancer Trials Ireland
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: * To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
This description comes directly from the study's public registry record.
Cancer Trials Ireland · info@cancertrials.ie
Always discuss trial participation with your own doctor first.
| Cork University Hospital | Cork, Ireland | Recruiting |
| Beaumont Hospital | Dublin, Ireland | Recruiting |
| St James's Hospital | Dublin, Ireland | Completed |
| St. Vincent's University Hospital | Dublin, Ireland | Recruiting |
| University Hospital Limerick | Limerick, Ireland | Active Not Recruiting |
| University Hospital Waterford | Waterford, Ireland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01840293